The Current Stage of Immunotherapy Development in the Breast Cancer Field

Natalie Kress

ABSTRACT:

Breast cancer is a disease that accounts for about 30% of all new cancer cases in women annually in the United States. It is also the deadliest cancer amongst women, taking 42,000 lives on average each year. Though most common in females, this devastating disease also affects male populations. Breast cancer starts when breast cells rapidly divide and grow, causing a tumor to form. Metastasis is the leading cause of death from breast cancer, as this tumor can spread to lymph nodes and other parts of the body. As of now, the standard of care for breast cancer includes surgery, chemotherapy, and radiation, however all of these treatments have harmful and long term side effects. In this review article, I will explore an emerging form of treatment called immunotherapy, a method that aims to use the power of the body's own immune system to target and kill breast cancer cells. Though still fairly experimental, many immunotherapy trials have shown promising results with fewer side effects than traditional systems of care. This article will delve into CAR-T cell therapy, TIL therapy, and monoclonal antibodies, including trastuzumab and pertuzumab.

BREAST CANCER OVERVIEW:

Breast cancer is the most common cancer among women globally, and the second most common cancer overall, only behind lung cancer. About 42,000 women and 500 men in the U.S. die each year from this disease (CDC Breast Cancer). This type of cancer occurs when the cells in the breast grow and divide uncontrollably, leading to the formation of a tumor. It can start in different parts of the breast, such as the ducts or lobules, and may spread to other parts of the body through the lymphatic system or bloodstream. Depending on location and size of the tumor, it can fall into different categories. Types of breast cancer include angiosarcoma, ductal carcinoma in situ (DCIS), inflammatory breast cancer, invasive lobular carcinoma, and lobular carcinoma in situ (LCIS), among others. Symptoms of breast cancer include changes in breast size or shape, nipple discharge, skin changes, or the presence of lumps (Mayo Clinic).

Breast cancer is typically diagnosed through a combination of methods, including clinical breast examination (CBE), breast ultrasound, mammography, magnetic resonance imaging (MRI), biopsy, and laboratory tests. CBE involves a physical examination of the breasts by a healthcare provider, while breast ultrasound uses sound waves to create images of breast tissue. A mammography is an examination that is done annually for women past the age of forty, and it uses X-rays to detect early signs of breast cancer. MRI uses powerful magnets and radio waves to create detailed images, and biopsy, which involves removing a small sample of breast tissue for examination under a microscope, is the definitive method for diagnosing breast cancer. Laboratory tests may be performed on the biopsy sample to determine the type and characteristics of it. Early detection through regular screenings and prompt evaluation of any breast abnormalities is crucial for the efficacy of breast cancer diagnosis and treatment. Factors such as family history, aging, being a woman, exposure to radiation, and certain chemicals can contribute to increased risk of developing breast cancer. Genetic mutations are also a major

factor. Mutations in certain genes, such as BRCA1 and BRCA2, which can be inherited from your parents, can increase the risk of breast cancer development. These genes normally produce proteins that help suppress the growth of tumors, but when mutated, their ability to regulate cell growth is impaired, leading to an increased risk (Mayo Clinic). While research and awareness campaigns have improved diagnosis, treatment, and survival rates, more efforts are needed to improve outcomes for all patients.

STANDARD TREATMENTS:

Breast cancer is a complex disease with various subtypes and stages which require a multi-faceted treatment approach. Over the years, significant advancements have been made in the standard treatments for breast cancer, resulting in improved survival rates and quality of life for patients. While this paper explores immunotherapies, the standard of care for breast cancer includes surgery, radiation, and chemotherapy.

Surgery:

Surgery is used for a large majority of people with breast cancer, and encompasses a range of procedures tailored to individual patient needs. The primary surgical options for breast cancer include breast-conserving surgery (lumpectomy) and mastectomy. Lumpectomy involves the removal of the tumor along with a margin of surrounding healthy tissue, aiming to achieve complete tumor removal while preserving the breast. This approach is typically followed by radiation therapy to eliminate any residual cancer cells and reduce the risk of local recurrence. Lumpectomy offers several advantages, including the preservation of breast appearance and sensation, and a shorter recovery period. This type of surgery also has a lower risk of complications compared to mastectomy, as mastectomy involves the complete removal of the breast tissue. Different types of mastectomy may be performed, such as total mastectomy, modified radical mastectomy, or skin-sparing mastectomy, depending on the extent of the surgery and individual patient factors. Mastectomy is often recommended for larger tumors, multifocal or multicentric cancers, genetic mutations (such as BRCA1 or BRCA2), or cases where breast-conserving surgery is not feasible or preferred by the patient. Immediate breast reconstruction can be performed at the time of mastectomy or delayed to a later stage. Reconstruction options include implant-based reconstruction, autologous tissue flap reconstruction (using the patient's own tissue), or a combination of both. The choice of reconstructive technique depends on the patient's preferences, body habitus, medical history, and oncological considerations. Advances in surgical techniques, such as oncoplastic surgery, have also contributed to improved outcomes by combining tumor removal with plastic surgery principles to achieve optimal cosmetic results. The decision between lumpectomy and mastectomy, as well as the timing and type of reconstruction, is highly individualized and should involve a multidisciplinary team comprising surgeons, oncologists, plastic surgeons, and the patient, taking into account the tumor characteristics, patient preferences, and psychosocial considerations (CDC Breast Cancer).

Radiation:

Radiation therapy plays a crucial role in the comprehensive treatment of breast cancer, serving as an essential component following breast-conserving surgery or mastectomy. This highly targeted and localized treatment method utilizes high-energy X-rays or other forms of radiation to destroy cancer cells and prevent them from regrowing. The primary goals of radiation in breast cancer management are to eliminate any residual cancer cells, reduce the risk of local recurrence, and improve overall survival rates. In the adjuvant setting, radiation therapy is typically recommended after a lumpectomy to ensure that any remaining cancer cells in the breast or surrounding tissues are effectively destroyed. This helps to reduce the likelihood of cancer recurrence in the treated area. Radiation may also be utilized in the neoadjuvant setting, administered prior to surgery, with the aim of shrinking tumors and facilitating surgical removal. There are many different types of radiation techniques that are used to deliver precise and accurate doses of radiation while minimizing exposure to healthy surrounding tissues. External beam radiation therapy (EBRT) is the most common form of radiation therapy for breast cancer. It involves the use of a linear accelerator machine to deliver radiation beams from outside the body to the affected breast area. Advanced techniques such as intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) allow for more precise targeting and customization of the radiation dose, minimizing damage to surrounding healthy tissues. Accelerated partial breast irradiation (APBI) is a method that delivers radiation specifically to the area of the breast where the tumor was removed, rather than treating the entire breast. This approach involves using brachytherapy or external beam radiation therapy with specialized devices to deliver a higher dose of radiation to the tumor bed over a shorter period. APBI is best suited for carefully selected patients with early-stage breast cancer and favorable tumor characteristics. Hypofractionated radiation therapy involves delivering a higher dose of radiation in fewer treatment sessions compared to conventional radiation therapy. This approach has been shown to be equally effective in controlling cancer while reducing the overall treatment time. Hypofractionated radiation therapy is particularly beneficial for patients who are unable to undergo longer courses of treatment or who live far from radiation facilities (CDC Breast Cancer).

Radiation therapy is generally well-tolerated, with side effects typically limited to the treated area. These may include skin changes like redness, irritation, or dryness, breast swelling, fatigue, and mild discomfort. Fortunately, these symptoms are usually temporary and can be managed with appropriate supportive care measures. Advances in radiation technology and techniques have greatly improved treatment precision and minimized the impact on healthy tissues, resulting in reduced long-term complications (CDC Breast Cancer).

Chemotherapy:

Chemotherapy uses the administration of powerful anti-cancer drugs that circulate throughout the body to target and kill cancer cells. Chemotherapy can be utilized in all steps of treatment, such as adjuvant therapy to eliminate any residual cancer cells, neoadjuvant therapy to shrink tumors prior to surgery, and as the primary treatment for advanced or metastatic breast cancer. The selection of chemotherapy drugs depends on several factors, including the subtype and stage of breast cancer, the presence of specific genetic mutations, and individual patient characteristics. Chemotherapy drugs can be administered orally or intravenously, and treatment regimens may consist of single drugs or combinations of drugs, tailored to the specific needs of each patient. This treatment works by interfering with the growth and division of rapidly dividing

cancer cells. It not only targets the primary tumor, but also helps to eradicate cancer cells that may have spread to other parts of the body. While chemotherapy is highly effective in killing cancer cells, it can also affect normal healthy cells, leading to harsh side effects. Common side effects of chemotherapy for breast cancer may include fatigue, hair loss, nausea, vomiting, loss of appetite, and increased susceptibility to infections. However, advances in supportive care measures have significantly improved the management of these side effects, helping patients tolerate and complete their chemotherapy treatments more effectively. In recent years, significant progress has been made in the field of chemotherapy for breast cancer. Personalized medicine approaches, such as genomic testing, allow for more targeted treatment decisions, enabling the selection of chemotherapy drugs that are most likely to be effective for a specific patient's tumor. Additionally, the development of new chemotherapy drugs and the use of combination therapies have led to improved treatment outcomes and prolonged survival for breast cancer patients (CDC Breast Cancer).

Though all these treatments may be more traditional, immunotherapies have brought significant advantages compared to the standard of care. One major advantage is their ability to harness the body's immune system to specifically target cancer cells. Unlike traditional therapies that primarily aim to kill rapidly dividing cells, immunotherapies stimulate the immune system to recognize and attack cancer cells more effectively. This targeted approach reduces the potential damage to healthy cells and tissues, leading to fewer side effects and improved quality of life for patients. Additionally, immunotherapies can elicit durable responses, with some patients experiencing long-term remission or even potential cures. Immunotherapies also have the potential to be used in combination with other treatments, such as chemotherapy or targeted therapies, to enhance their effectiveness. This offers the possibility of personalized medicine, as they can be tailored to target specific molecular markers or antigens present on cancer cells, making them particularly suitable for patients with specific subtypes of breast cancer. While immunotherapies may be more experimental than standard treatments such as chemo or radiation, they represent a promising frontier in breast cancer treatment, offering new hope and improved outcomes for patients (CDC Breast Cancer).

WHAT ARE IMMUNOTHERAPIES?:

Breast cancer immensely affects the immune system, leading to a range of immune-related changes. This disease manipulates the immune response by releasing substances that suppress immune cells and inhibit their activity. Breast tumors create a unique microenvironment that hampers immune responses and fosters the growth of cancer cells. Moreover, breast cancer cells can disrupt the normal functioning of immune cells, impairing their ability to recognize and attack cancer cells. The spread of breast cancer to other parts of the body, known as metastasis, requires the cancer cells to evade immune surveillance. Additionally, breast cancer and its treatments can induce systemic inflammation and immune dysfunction, making patients more vulnerable to infections. Despite these challenges, researchers are actively developing immunotherapies to enhance the immune response against breast cancer, aiming to restore and strengthen the immune system's ability to combat breast cancer (Amens et al.). Immunotherapy is a rapidly evolving field of medicine that involves harnessing the power of the body's immune system to treat a wide range of diseases. This

approach uses the activation or enhancement of the immune system to recognize and attack abnormal or damaging cells while leaving healthy cells unharmed. One type of immunotherapy involves using monoclonal antibodies, which are artificially created immune system proteins designed to target specific antigens found on the surface of cancer cells or pathogens. These antibodies can help the immune system to identify and destroy cancer cells or to fight off infectious agents. Another approach uses checkpoint inhibitors, which block proteins that limit the immune system's ability to attack cancer cells. By removing these "brakes," the immune system can more effectively target and destroy these cells. Immunotherapy can also involve using vaccines to stimulate the immune system to recognize and attack specific cancer cells or infectious agents. In some cases, immune cells may be removed from a patient's body, modified to enhance their cancer-fighting abilities, and then reintroduced into the patient's system.

Immunotherapy can be used to treat a variety of conditions, including cancer, autoimmune disorders, and infectious diseases. This form of treatment has the potential to offer a more targeted and effective approach to treating a variety of diseases, while minimizing side effects associated with traditional treatments like chemotherapy and radiation therapy. While this field of medicine is still in its early stages, ongoing research and clinical trials are helping to expand our understanding of how to use immunotherapy to improve patient outcomes (American Cancer Society).

CAR-T CELL THERAPY:

Chimeric antigen receptor T-cell therapy (CAR-T cell therapy) is a form of immunotherapy treatment in which the patient’s own T cells are genetically modified to recognize and attack cancer cells. This process begins by removing T cells from the patient’s blood in a procedure called leukapheresis, which is a medical procedure that involves the separation and collection of white blood cells, specifically leukocytes, from the blood. It is typically performed using a specialized machine called a leukapheresis machine, which is similar to a blood donation machine. During leukapheresis, blood is drawn from a patient's vein and passed through the machine, which separates the white blood cells from the rest of the blood components, like red blood cells and plasma. The separated T cells are then collected and the remains are returned to the patient. Those T cells are then altered ex vivo by putting in chimeric antigen receptors (CAR) that will recognize a specific protein on the surface of cancer cells, such as human epidermal growth factor receptor 2 (HER2) or MUC1, which are often overexpressed in breast cancer cells, and are cultured to multiply. After a certain amount is produced, the T cells are put back into the patient’s body, with the hope that they will start to attack cancer cells (National Cancer Institute).

One CAR-T cell therapy trial for breast cancer that has gained attention is a Phase I/II clinical trial led by researchers at the National Cancer Institute (NCI) in the United States. The trial is investigating the safety and efficacy of CAR-T cell therapy in treating advanced HER2-positive breast cancer, which accounts for approximately 25% of all breast cancers. In this type of breast cancer, its tumor cells have an overexpression of the HER2 protein, which promotes the growth and survival of cancer cells. The CAR-T cell therapy being tested in this trial targets the HER2 protein on the surface of cancer cells, allowing the modified immune cells to specifically target and attack the cancer cells (Bellicum Pharmaceuticals). The trial involves collecting T cells from the patient's blood and modifying them in the laboratory to express a CAR

that recognizes HER2. It uses a form of CAR T-cell therapy called BPX-603, developed by Bellicum Pharmaceuticals. This treatment has a controllable dual-switch CAR T-cell which uses chemical inducer of dimerization (CID) technology. CID technology means that two proteins only dimerize, or combine, in the presence of another small molecule called a ligand. For this specific technology, GoCAR-T and CaspaCIDe molecular switches are utilized. In order for the GoCAR-T molecular switch to function, rimiducid, a type of ligand, is administered, which leads to the activation of MyD88/CD40. In result, the T-cells are able to more effectively target HER2 cancer cells. The CaspaCIDe molecular switch functions as a safety mechanism, and uses the same method to activate iCasp9 (National Cancer Institute). This enzyme can recognize and eliminate ineffective engineered T-cells. There is a targeted enrollment of 220 patients with advanced HER2-positive breast cancer who have previously received standard treatments such as chemotherapy. The results have been promising, with several patients experiencing significant reductions in tumor size and improved overall survival. However, the treatment has also been associated with some side effects, including fever, low blood cell counts, and neurotoxicity. This trial has unfortunately been suspended due to a dose limiting toxicity in another sister trial using the same technology (Seymour). However, if resumed, CAR-T cell therapy could represent a new and effective treatment option for patients with advanced HER2-positive breast cancer who have exhausted other treatment options.

TIL THERAPY:

Tumor infiltrating lymphocyte therapy (TIL therapy) involves isolating T cells from a patient's tumor, growing them in the lab, and then infusing them back into the patient to fight the cancer. This is often done before CAR-T cell therapy because it helps solve the problem of drug resistance of solid tumors to PD-1 antibodies. The first step in TIL therapy is to obtain a small sample of the patient's tumor tissue through a biopsy or surgical resection. Once the tumor tissue has been collected, it is processed in the laboratory to isolate the lymphocytes, which are a type of white blood cell that plays a key role in the immune response against cancer cells. The lymphocytes are separated from other cells in the tumor tissue and purified for further use in the therapy. The isolated lymphocytes are then activated in the laboratory using various techniques, such as exposing them to special proteins called cytokines that stimulate their growth and activity. This activation step helps to "prime" the lymphocytes and prepare them for their anti-cancer activity. After activation, the lymphocytes are cultured in the laboratory to stimulate their proliferation and expansion, resulting in a larger number of activated lymphocytes that can be used in the therapy. This process may take several weeks to generate a sufficient number of lymphocytes for infusion (National Cancer Institute).

Prior to the infusion of the expanded TILs, the patient may receive a pre-conditioning treatment, such as chemotherapy or radiation therapy, to help prepare the body for the incoming TILs. This pre-conditioning treatment may help suppress the patient's immune system and create a more favorable environment for the TILs to effectively target the cancer cells. Once a sufficient number of activated lymphocytes are obtained, they are infused back into the patient's bloodstream, similar to a blood transfusion. The infused TILs then travel throughout the body, seeking out and attacking cancer cells wherever they are present, including the primary tumor and any metastatic lesions. After the TIL infusion, the patient is closely monitored for any adverse reactions or side effects. Regular follow-up evaluations, including imaging studies and

blood tests, are conducted to assess the effectiveness of the therapy and monitor the patient's response to treatment (National Cancer Institute).

TIL therapies are still fairly experimental, however they have shown promising antitumor effects in many trials. One notable TIL therapy trial for breast cancer is a Phase II clinical trial led by researchers at the National Cancer Institute (NCI) in the United States. The trial is testing out TIL therapy for treating patients with metastatic TNBC who have previously received standard treatments such as chemotherapy. The trial involves the standard TIL therapy process, extracting TILs from a patient's tumor, growing them in a laboratory, and then re-infusing them back into the patient's body after the patient undergoes a lymphodepleting chemotherapy regimen. The goal of the lymphodepleting chemotherapy is to reduce the number of immune cells in the body, making it easier for the infused TILs to multiply and attack the cancer cells. As of the latest update in 2023, the trial has an estimated enrollment of 332 patients with metastatic TNBC. The results have been encouraging, with some patients experiencing significant reductions in tumor size and improved overall survival. Despite these promising results, the treatment has also been associated with side effects including fever, low blood cell counts, and inflammation. The trial is still continuing, and researchers continue to monitor patients for safety and efficacy. If successful, TIL therapy could represent a new and safe treatment option for patients with metastatic TNBC who have tried other treatment options and are still sick. However, further studies are needed to determine the optimal dosing and timing of TIL therapy and to identify biomarkers that can predict which patients are most likely to benefit from this treatment (NIH Clinical Center).

MONOCLONAL ANTIBODIES:

Monoclonal antibodies have emerged as an important option for the treatment of breast cancer. These antibodies are designed to specifically target and bind to certain proteins or receptors present on cancer cells, thereby inhibiting their growth and promoting immune responses against the cancer (Schneble et al.).

Trastuzumab:

One of the most well-known monoclonal antibodies used in breast cancer treatment is trastuzumab. Trastuzumab, marketed under the brand name Herceptin, is a monoclonal antibody that has revolutionized the treatment of breast cancer, specifically for patients with HER2-positive breast cancer. HER2 is a protein that plays a critical role in the growth and division of cells. However, when HER2 is overexpressed, as seen in approximately 20-25% of breast cancer cases, it can contribute to aggressive tumor growth and poorer prognosis. By binding to the HER2 receptor on the surface of cancer cells, trastuzumab interferes with the receptor's signaling pathway, leading to reduced cancer cell proliferation and survival. Trastuzumab can also elicit immune responses against HER2-positive cancer cells, further enhancing its tumor-killing effects. The use of trastuzumab in the treatment of HER2-positive breast cancer has demonstrated significant clinical benefits. It has been shown to improve both disease-free survival and overall survival in early-stage and advanced-stage HER2-positive breast cancer patients. Trastuzumab is typically administered intravenously and is commonly used in combination with chemotherapy or other targeted therapies. This drug is often given for

a period of one year, either with or following chemotherapy. Its use has significantly reduced the risk of disease recurrence in HER2-positive breast cancer patients. In metastatic breast cancer, trastuzumab is often used in combination with chemotherapy or other HER2-targeted agents to control disease progression and improve patient outcomes. While trastuzumab has demonstrated remarkable efficacy, it can also have side effects. The most notable being its potential damage to the heart muscle, leading to cardiac dysfunction. Because of this, close monitoring of cardiac function is necessary during treatment. Other common side effects of trastuzumab include infusion-related reactions, fatigue, nausea, and diarrhea. Over the years, trastuzumab has paved the way for the development of other HER2-targeted therapies, including pertuzumab and ado-trastuzumab emtansine (T-DM1). Combination therapies involving trastuzumab have shown improved outcomes in HER2-positive breast cancer patients, providing additional treatment options and improving the chances of successful treatment (Cancer Research UK).

Pertuzumab:

Like mentioned above, another monoclonal antibody used in breast cancer treatment is pertuzumab. Pertuzumab, or perjeta, is a drug that is used to target a different part of the HER2 protein than trastuzumab, and works by blocking the interaction between HER2 and another receptor called HER3, thus restricting cancer cell growth and survival. Pertuzumab is typically used in combination with trastuzumab and chemotherapy in the neoadjuvant, adjuvant, and metastatic settings for HER2-positive breast cancer. The combination of pertuzumab and trastuzumab has been shown to improve clinical outcomes and survival rates in patients with early-stage and advanced-stage HER2-positive breast cancer. In the neoadjuvant setting, pertuzumab is typically administered prior to surgery in order to shrink tumors and increase the chances of successful surgical removal. In the adjuvant setting, pertuzumab is given along with trastuzumab and chemotherapy to reduce the risk of disease recurrence. In metastatic breast cancer, the combination of pertuzumab and trastuzumab is used to control disease progression and improve overall survival. This drug has demonstrated efficacy in improving survival outcomes for HER2-positive breast cancer patients. Clinical trials have shown that the addition of pertuzumab to standard treatment regimens significantly increases response rates and prolongs progression-free survival. Furthermore, combining pertuzumab with trastuzumab has shown synergistic effects, providing enhanced HER2 blockade and improved clinical benefits. However, like other breast cancer treatments, pertuzumab may have side effects. Common side effects include infusion-related reactions, diarrhea, nausea, fatigue, and decreased appetite. Additionally, like trastuzumab, pertuzumab treatment requires monitoring of cardiac function due to the risk of cardiac toxicity. This drug has expanded the therapeutic options available for HER2-positive breast cancer, providing an additional targeted therapy to enhance treatment efficacy. Its use in combination with trastuzumab and chemotherapy has become a standard of care in the management of HER2-positive breast cancer, demonstrating the benefits of personalized treatment approaches and improved patient outcomes. Ongoing research continues to explore the optimal sequencing and combination strategies involving pertuzumab, trastuzumab, and other HER2-targeted agents, aiming to further enhance treatment responses and expand treatment options for HER2-positive breast cancer patients (Cancer Research UK).

The field of monoclonal antibody therapy for breast cancer continues to evolve, with ongoing research and development of novel antibodies and combination therapies. Researchers are exploring new targets and mechanisms of action to improve treatment outcomes and address different subtypes of breast cancer.

CONCLUSION:

Each year in the United States, about 264,000 cases of breast cancer are diagnosed in women and about 2,400 in men. Despite these statistics, there's still no completely effective treatment. The current standard of care involves surgery, chemotherapy, and radiation, however all these methods have extreme side effects that can be devastating for the patients' quality of life. In order to kill breast cancer cells, these approaches are very aggressive, and can destroy healthy cells in the process. To address this concern, there have been efforts to explore more targeted treatments. Immunotherapies have opened up new breakthroughs for the treatment of breast cancer, offering potential benefits beyond conventional therapies. They harness the power of the immune system to recognize, target, and destroy cancer cells more effectively. CAR-T cell therapy is an emerging treatment approach for breast cancer in which T cells are collected from the patient's blood and genetically modified to express a chimeric antigen receptor (CAR) on their surface. The CAR enables the T cells to recognize and bind to specific antigens present on breast cancer cells. Once infused back into the patient's body, these CAR-T cells target and attack the cancer cells, leading to their destruction. TIL therapy involves extracting immune cells, specifically T cells, from a patient's tumor tissue. These T cells, known as tumor-infiltrating lymphocytes (TILs), are then isolated, expanded, and activated in the laboratory to enhance their anti-tumor properties. After the TILs are grown in large numbers, they are infused back into the patient's body. The activated TILs are designed to recognize and target the cancer cells specifically, effectively attacking and eliminating them. TIL therapy has shown promising results in some patients with advanced or metastatic breast cancer. Monoclonal antibodies are laboratory-produced molecules designed to target specific proteins or receptors on cancer cells. They are often directed against proteins like HER2 (human epidermal growth factor receptor 2) or hormone receptors such as estrogen receptor (ER) or progesterone receptor (PR). By binding to these targets, monoclonal antibodies can interfere with cancer cell growth and survival, trigger immune responses against the tumor, or enhance the effects of other treatments. They can be used as standalone therapies or in combination with chemotherapy or other targeted therapies. Monoclonal antibodies have demonstrated significant efficacy in various stages of breast cancer, including early-stage and metastatic disease, offering patients new treatment options and improved outcomes. While challenges remain, such as identifying the most appropriate patient populations, managing potential side effects, and, most importantly, ensuring the specific targeting of cancer cells, immunotherapies represent a significant step forward in the fight against breast cancer. Continued research and clinical trials will pave the way for improved treatment outcomes and the possibility of a cure for this devastating disease.

BIBLIOGRAPHY:

[1] Amens, Jensen N., et al. “Immune System Effects on Breast Cancer.” *Cellular and Molecular Bioengineering*, vol. 14, no. 4, 3 June 2021, pp. 279–292, https://doi.org/10.1007/s12195-021-00679-8.

[2] American Cancer Society. “Immunotherapy for Breast Cancer | Breast Cancer Treatment.” *Www.cancer.org*, 17 Oct. 2021, www.cancer.org/cancer/types/breast-cancer/treatment/immunotherapy.html.

[3] Bellicum Pharmaceuticals. “A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects with Previously Treated Advanced HER2-Positive Solid Tumors.” *Clinicaltrials.gov*, 10 Aug. 2022, clinicaltrials.gov/ct2/show/NCT04650451.

[4] Breastcancer.org. “Breast Cancer Facts and Statistics.” *Www.breastcancer.org*, 10 Mar. 2022, www.breastcancer.org/facts-statistics.

[5] Cancer Research UK. “Pertuzumab (Perjeta).” *Www.cancerresearchuk.org*, 19 Jan. 2023, www.cancerresearchuk.org/about-cancer/treatment/drugs/pertuzumab.

[6] ---. “Trastuzumab (Herceptin) | Cancer Information | Cancer Research UK.” *Www.cancerresearchuk.org*, 16 Apr. 2021, www.cancerresearchuk.org/about-cancer/treatment/drugs/trastuzumab.

[7] CDC Breast Cancer. “Basic Information about Breast Cancer.” *Centers for Disease Control and Prevention*, 14 Sept. 2020, www.cdc.gov/cancer/breast/basic_info/index.htm#:~:text=Each%20year%20in%20the%20United.

[8] Mayo Clinic. “Breast Cancer - Symptoms and Causes.” *Mayo Clinic*, Mayo Clinic, 27 Apr. 2022, www.mayoclinic.org/diseases-conditions/breast-cancer/symptoms-causes/syc-20352470.

[9] National Cancer Institute. “CAR T Cells: Engineering Immune Cells to Treat Cancer.” *National Cancer Institute*, Cancer.gov, 10 Mar. 2022, www.cancer.gov/about-cancer/treatment/research/car-t-cells.

[10] ---. “Experimental Immunotherapy Targets Metastatic Breast Cancer - National Cancer Institute.” *Www.cancer.gov*, 1 Feb. 2022, www.cancer.gov/news-events/press-releases/2022/personalized-immunotherapy-metastatic-breast-cancer.

[11] ---. “Https://Www.cancer.gov/Publications/Dictionaries/Cancer-Drug/Def/Autologous-Her2-Targeted-Dual-Switch-Car-t-Cells-Bpx-603.” *Www.cancer.gov*, 2 Feb. 2011, www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-her2-targeted-dual-switch-car-t-cells-bpx-603. Accessed 21 June 2023.

[12] NIH Clinical Center. “Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients with Metastatic Cancer - Full Text View - ClinicalTrials.gov.” *Clinicaltrials.gov*, 18 June 2023, classic.clinicaltrials.gov/ct2/show/NCT01174121. Accessed 21 June 2023.

[13] Schneble, Erika, et al. “Breast Cancer Immunotherapy.” *Maedica*, vol. 10, no. 2, 2015, pp. 185–191, www.ncbi.nlm.nih.gov/pmc/articles/PMC5327815/#:~:text=Passive%20immunotherapy%20has%20provided%20several. Accessed 21 June 2023.

[14] Seymour, Caroline. “BPX-601 and BPX-603 Trials Discontinued in Advanced Solid Tumors.” *OncLive*, 15 Mar. 2023, www.onclive.com/view/bpx-601-and-bpx-603-trials-discontinued-in-advanced-solid-tumors. Accessed 21 June 2023.

[15] UnityPoint Health. “Most Dangerous Cancers in Men and Women.” *Www.unitypoint.org*, www.unitypoint.org/news-and-articles/most-dangerous-cancers-in-men-and-women.